U.S. Hemophilia Treatment Market ANALISI DIMENSIONE E QUOTA - TENDENZE DI CRESCITA E PREVISIONI (2024 - 2031)

U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.

Competitive overview of U.S. Hemophilia Treatment Market

I principali giocatori che operano nel mercato del trattamento emofilia statunitense includono Takeda Pharmaceutical Company Limited., Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc. e Spark Therapeutics, Inc.

U.S. Hemophilia Treatment Market Leaders

  • Takeda Farmaceutica Società Limitata
  • Sanofi Octapharma AG
  • Orfano svedese Biovitrum AB
  • Baxter Internazionale Inc.
  • Biogen Inc.
*Disclaimer: Major players are listed in no particular order.

U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023

Market Concentration Graph

U.S. Hemophilia Treatment Market

Market Consolidated
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
*Source: Coherent Market Insights

U.S. Hemophilia Treatment Market Report Snapshots

Buy Now